BioCryst Pharma (BCRX) Appoints Steve Frank to its Board

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors.

Mr. Frank serves as chairman of global healthcare investment banking at J.P. Morgan. He was previously global group head of worldwide healthcare investment banking at Bear Stearns before it was acquired by J.P. Morgan in 2008. Mr. Frank is a trusted corporate advisor, supporting countless transactions including pharmaceutical, biotechnology, medical device and healthcare services firms. A standout institutional investor before becoming a banker, Mr. Frank directed and built State Farm’s multi-billion-dollar life science equity portfolio in the 1980s and early 1990s. He maintains the accreditation as a Chartered Financial Analyst today.

“Steve is one of the most accomplished and respected healthcare investment bankers in the industry and we look forward to adding his expertise to the board. His experience with innovative business development transactions and value-creating capital allocation are a perfect fit as BioCryst builds on its commercial success, accelerates towards profitability and advances its pipeline,” said Dr. Nancy Hutson, chair of the BioCryst board of directors.

“BioCryst is uniquely positioned in the biopharma space with the rare combination of a commercial product growing closer to $1 billion in peak sales, a strong cash position that makes the company independent of the capital markets, and a next wave of potential best-in-class medicines in the clinic. I am excited to join this world-class board at such an important time for the company,” Mr. Frank said.

Mr. Frank currently serves on the board of Precigen. He holds a B.S. from Illinois State University and an M.B.A. from the University of Chicago.

You May Also Be Interested In

• Shutterstock and Getty Images merger terminated after CMA conditions
• Rivian raises $1.32 billion in stock offering to fund DOE loan equity
• Citi names top picks in software ahead of Q2 earnings